Microbio

16/03/2026

We are delighted to welcome Ana Illera López to Microbio as our new Field Application Specialist!

Based in Spain, Ana brings a strong combination of scientific expertise, hands-on technical experience, and international perspective that will support customers and partners across Europe as they adopt InfectID™-BSI.

Ana holds a PhD in Human Genetics and an MRes in Biomedical Sciences and Translational Medicine from the University of Liverpool, along with a BSc in Genetics and Cell Biology. Her career has taken her across Spain, the United Kingdom, and Ireland, giving her valuable experience working across different scientific and clinical environments.

Ana's technical expertise, communication skills, and customer-focused approach will be invaluable as she supports customers and distributors implementing InfectID™-BSI, Microbio's rapid qPCR-based diagnostic designed to enable faster pathogen identification in sepsis and support more targeted treatment decisions.

Welcome to the team, Ana!

22/12/2025

Early pathogen identification plays a critical role in antimicrobial stewardship, especially in patients with suspected sepsis.

When clinicians have faster insight into the likely cause of infection, they can move beyond prolonged empirical therapy and make more informed treatment decisions. This supports antimicrobial stewardship efforts and helps protect the effectiveness of existing therapies.

Read our latest blog post to explore why timing matters more than ever.
👉 https://hubs.li/Q03YTq3x0

09/12/2025

Each year, sepsis affects an estimated 49 million people worldwide including over 20 million children under 5 and nearly 5 million older children and teens.

This life-threatening condition can escalate quickly, but early detection saves lives. At Microbio, we’re committed to developing rapid, accurate diagnostics to help clinicians detect infections faster and act sooner.

Because every life counts.

01/12/2025

Today, on World AIDS Day, we acknowledge the ongoing global effort to address HIV and related infectious diseases. Effective diagnostics remain central to that effort. When clinicians have access to fast, accurate results, they can make better decisions for their patients and strengthen public health responses at scale.

At Microbio, our work focuses on providing tools that support early detection of infectious agents. Accessible diagnostics are a key part of improving outcomes for communities everywhere.

20/11/2025

Your Sepsis Diagnostics Questions, Answered

Clinicians and partners often ask the same core questions about how sepsis is diagnosed and where molecular testing fits.

Our latest FAQ article brings these answers together in one place. It covers:
• How sepsis is identified in clinical practice
• The role of biomarkers, cultures and molecular methods
• Where InfectID™-BSI fits into the diagnostic pathway
• How faster identification can support antimicrobial stewardship
• What support Microbio provides to customers and partners

If you’re looking for a clear overview, this is a great starting point.

18/11/2025

World AMR Awareness Week runs from 18 to 24 November. It is a global campaign dedicated to improving understanding of antimicrobial resistance and encouraging best practices that help slow the rise and spread of drug-resistant infections.

This year’s theme, “Act Now. Protect Our Present, Secure Our Future”, highlights the need for coordinated action across sectors. AMR is already shaping health outcomes, food systems, environmental stability and economies. It is not a distant challenge. It is a current and growing threat that requires immediate and sustained attention.

At Microbio, we contribute to stewardship efforts by helping clinicians reach targeted therapy sooner. InfectID-BSI identifies 26 pathogens associated with sepsis in three hours. This supports more informed treatment decisions and can reduce the reliance on broad empirical therapy when rapid clarity matters.

AMR cannot be addressed by awareness alone. It relies on better diagnostics, responsible antibiotic use and collaboration across sectors. This week is a reminder of the steps we can take today to protect treatment options for the future.

12/11/2025

Our InfectID™-BSI test is designed to accurately identify 26 sepsis-causing pathogens in just 3 hours, providing healthcare providers with the critical time needed to deliver targeted treatments.

In the fight against sepsis, every hour matters ⌛. Quick and precise diagnosis can significantly improve patient outcomes and potentially save lives. By reducing the time to diagnosis, we empower healthcare professionals to make informed decisions, leading to timely interventions and better care for patients facing this life-threatening condition.

04/11/2025

When the Standard of Care cannot identify fastidious or suppressed pathogens, timely and targeted treatment is delayed. InfectID™-BSI changes that, delivering rapid and reliable pathogen identification in just three hours.

🔍 Why it matters:
- Improves accuracy for patients with prior antimicrobial therapy.
- Enhances detection of hard-to-culture pathogens.

Learn more about how InfectID™-BSI is addressing these challenges: https://hubs.li/Q03RhxsM0

30/10/2025

Antimicrobial resistance (AMR) continues to accelerate worldwide, with the latest WHO report revealing that one in six bacterial infections in 2023 was resistant to antibiotic treatment. Gram-negative bacteria, such as E. coli and K. pneumoniae, are now showing resistance rates exceeding 40% globally.

These pathogens are among the leading causes of bloodstream infections that can progress to sepsis, where rapid identification is critical.

At Microbio, our InfectID™-BSI test identifies 26 pathogens associated with bloodstream infections, including E. coli and K. pneumoniae, within three hours. This provides clinicians with the information needed to prescribe targeted antibiotics.

As AMR continues to rise, especially in regions with limited diagnostic capacity, rapid molecular tests like InfectID™-BSI are essential tools to help clinicians act fast, preserve treatment options, and improve patient outcomes.

One in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments, according to a new World Health Organization (WHO) report launched today.

29/10/2025

Microbio Enters Danish Market Through Partnership with YouDoBio

Microbio has signed an exclusive distribution agreement with YouDoBio, a molecular diagnostics provider based in Denmark.

Through this partnership, Danish clinicians and laboratories will gain access to InfectID™-BSI, Microbio’s rapid molecular assay that identifies 26 bloodstream infection pathogens directly from blood samples in just three hours.

With YouDoBio’s deep expertise and established presence in Danish healthcare, this collaboration supports faster, more targeted treatment decision.

This agreement marks another key milestone in Microbio’s European expansion strategy.

Read more: https://hubs.li/Q03QJ3GS0

27/10/2025

By the time you read this post, 21 people will have died of sepsis.

According to a 2020 World Health Organisation report, 49 million people get sepsis each year. 21 people die every minute.

At Microbio, we’re dedicated to changing these statistics with faster, more targeted pathogen detection. Because early diagnosis saves lives.

Learn more: https://hubs.li/Q03QbmS_0

24/10/2025

Microbio is pleased to announce the appointment of Dr. Lutz Bonacker as Chief Commercial Officer.

With over 30 years of global experience in healthcare and biotechnology — including two decades at CSL Behring, where he led commercial strategy and operations across Europe — Dr Bonacker brings deep expertise in commercialising innovative therapies and building high-performing teams.

His appointment strengthens Microbio’s leadership as we advance the global commercialisation of InfectID™-BSI, our rapid molecular diagnostic for sepsis-related pathogens.

🔗 Read the full announcement on our website: https://hubs.ly/Q03P_8FX0